Novavax's COVID-19 Vaccine Nears FDA Full Approval, Stock Jumps
1. Novavax's stock rose 19.5% amidst a BLA filing update. 2. FDA considers Novavax's BLA approvable but requests more clinical data. 3. SHIELD-Utah study shows Novavax's vaccine has favorable reactogenicity results. 4. Moving average for NVAX sits at $9.94, above current price of $7.33. 5. Analysts suggest bullish sentiment based on technical indicators and recent gains.